The reform raised concerns about increased use of insulin in the treatment of type 2 diabetes for economic rather than clinical reasons because the co-payment of insulin was not affected by the reform and remained fully covered (with a fixed fee of €4.50 per dispensing) (Government Proposal 184/2016; Lahtela, 2017). This evidence concerns the gene INS and type 2 diabetes mellitus.